Similar articles

• Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research.

  Hopkins ZH, Secrest AM. Hopkins ZH, et al. JAMA Dermatol. 2020 Sep 1;156(9):1028-1029. doi: 10.1001/jamadermatol.2020.1310. JAMA Dermatol. 2020. PMID: 32520342 No abstract available.
• Reply to Letter: Effectiveness of Mohs and Close.

  Gloster HM Jr. Gloster HM Jr. J Drugs Dermatol. 2018 Mar 1;17(3):368-369. J Drugs Dermatol. 2018. PMID: 29537457
• Reply to "Comment on 2012 appropriate use criteria for Mohs micrographic surgery".

  Ad Hoc Task Force on Appropriate Use Criteria for Mohs Microsurgery; Connolly S, Baker D, Coldiron B, Fazio M, Storrs P, Vidimos A, Zalla M, Smith Begolka W. Ad Hoc Task Force on Appropriate Use Criteria for Mohs Microsurgery, et al. J Am Acad Dermatol. 2013 Aug;69(2):318. doi: 10.1016/j.jaad.2013.04.014. J Am Acad Dermatol. 2013. PMID: 23866872 No abstract available.
• Mohs micrographic surgery for thin stage I malignant melanoma: rationale for a modern management strategy.

  Kaspar TA, Wagner RF Jr. Kaspar TA, et al. Cutis. 1992 Nov;50(5):350-1. Cutis. 1992. PMID: 1468255 Review.
• Mohs surgery for melanoma in situ.

  Kwon SY, Miller SJ. Kwon SY, et al. Dermatol Clin. 2011 Apr;29(2):175-83, vii-viii. doi: 10.1016/j.det.2011.01.001. Dermatol Clin. 2011. PMID: 21421143 Review.